ONCODESIGN PRECISION MEDICIN (ALOPM.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:ALOPM • FR001400CM63

0.568 EUR
-0.02 (-3.07%)
Last: Feb 4, 2026, 07:00 PM
Fundamental Rating

2

Overall ALOPM gets a fundamental rating of 2 out of 10. We evaluated ALOPM against 84 industry peers in the Biotechnology industry. Both the profitability and financial health of ALOPM have multiple concerns. ALOPM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ALOPM had negative earnings in the past year.
  • ALOPM had negative earnings in each of the past 5 years.
  • ALOPM had a negative operating cash flow in each of the past 5 years.
ALOPM.PA Yearly Net Income VS EBIT VS OCF VS FCFALOPM.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • ALOPM's Return On Assets of -2.18% is fine compared to the rest of the industry. ALOPM outperforms 67.86% of its industry peers.
Industry RankSector Rank
ROA -2.18%
ROE N/A
ROIC N/A
ROA(3y)-38.13%
ROA(5y)-30.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALOPM.PA Yearly ROA, ROE, ROICALOPM.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

  • With an excellent Gross Margin value of 100.25%, ALOPM belongs to the best of the industry, outperforming 98.81% of the companies in the same industry.
  • ALOPM's Gross Margin has been stable in the last couple of years.
  • ALOPM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.78%
GM growth 5YN/A
ALOPM.PA Yearly Profit, Operating, Gross MarginsALOPM.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ALOPM has more shares outstanding
  • The debt/assets ratio for ALOPM is higher compared to a year ago.
ALOPM.PA Yearly Shares OutstandingALOPM.PA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
ALOPM.PA Yearly Total Debt VS Total AssetsALOPM.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • ALOPM has an Altman-Z score of -1.38. This is a bad value and indicates that ALOPM is not financially healthy and even has some risk of bankruptcy.
  • ALOPM has a Altman-Z score of -1.38. This is in the lower half of the industry: ALOPM underperforms 64.29% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.38
ROIC/WACCN/A
WACCN/A
ALOPM.PA Yearly LT Debt VS Equity VS FCFALOPM.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M 4M 6M 8M 10M

2.3 Liquidity

  • A Current Ratio of 0.87 indicates that ALOPM may have some problems paying its short term obligations.
  • With a Current ratio value of 0.87, ALOPM is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.87 indicates that ALOPM may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.87, ALOPM is not doing good in the industry: 70.24% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.87
ALOPM.PA Yearly Current Assets VS Current LiabilitesALOPM.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ALOPM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.37%, which is quite good.
  • The Revenue for ALOPM has decreased by -80.37% in the past year. This is quite bad
  • The Revenue for ALOPM have been decreasing by -62.01% on average. This is quite bad
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-80.37%
Revenue growth 3Y-62.01%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ALOPM will show a very strong growth in Earnings Per Share. The EPS will grow by 49.26% on average per year.
  • The Revenue is expected to grow by 78.65% on average over the next years. This is a very strong growth
EPS Next Y95%
EPS Next 2Y247.49%
EPS Next 3Y49.26%
EPS Next 5YN/A
Revenue Next Year151.06%
Revenue Next 2Y365.39%
Revenue Next 3Y78.65%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALOPM.PA Yearly Revenue VS EstimatesALOPM.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
ALOPM.PA Yearly EPS VS EstimatesALOPM.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ALOPM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ALOPM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALOPM.PA Price Earnings VS Forward Price EarningsALOPM.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALOPM.PA Per share dataALOPM.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

  • ALOPM's earnings are expected to grow with 49.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y247.49%
EPS Next 3Y49.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ALOPM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ONCODESIGN PRECISION MEDICIN

EPA:ALOPM (2/4/2026, 7:00:00 PM)

0.568

-0.02 (-3.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)04-03
Inst Owners0.2%
Inst Owner ChangeN/A
Ins Owners8.7%
Ins Owner ChangeN/A
Market Cap10.33M
Revenue(TTM)7.98M
Net Income(TTM)-240.00K
Analysts84.44
Price Target2.04 (259.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.29
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.44
BVpS0
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100.25%
FCFM N/A
ROA(3y)-38.13%
ROA(5y)-30.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.78%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.87
Altman-Z -1.38
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y95%
EPS Next 2Y247.49%
EPS Next 3Y49.26%
EPS Next 5YN/A
Revenue 1Y (TTM)-80.37%
Revenue growth 3Y-62.01%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year151.06%
Revenue Next 2Y365.39%
Revenue Next 3Y78.65%
Revenue Next 5YN/A
EBIT growth 1Y21.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.11%
EBIT Next 3Y52.59%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ONCODESIGN PRECISION MEDICIN / ALOPM.PA FAQ

What is the ChartMill fundamental rating of ONCODESIGN PRECISION MEDICIN (ALOPM.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALOPM.PA.


What is the valuation status of ONCODESIGN PRECISION MEDICIN (ALOPM.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to ONCODESIGN PRECISION MEDICIN (ALOPM.PA). This can be considered as Overvalued.


How profitable is ONCODESIGN PRECISION MEDICIN (ALOPM.PA) stock?

ONCODESIGN PRECISION MEDICIN (ALOPM.PA) has a profitability rating of 2 / 10.


Can you provide the financial health for ALOPM stock?

The financial health rating of ONCODESIGN PRECISION MEDICIN (ALOPM.PA) is 0 / 10.